[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Zhou, 2009 - Google Patents

Enhanced anti-tumor immunity by breaking immune tolerance

Zhou, 2009

View PDF
Document ID
2070454579099350831
Author
Zhou P
Publication year

External Links

Snippet

ProQuest Dissertations Page 1 ENHANCED ANTI-TUMOR IMMUNITY BY BREAKING IMMUNE TOLERANCE By Penghui Zhou A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Immunology) The University of …
Continue reading at deepblue.lib.umich.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
US10822588B2 (en) Agents and methods to elicit anti-tumor immune response
US20230355732A1 (en) Tumor Antigens for Determining Cancer Therapy
Chen et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model
Coquet et al. Epithelial and dendritic cells in the thymic medulla promote CD4+ Foxp3+ regulatory T cell development via the CD27–CD70 pathway
Dunn et al. Cancer immunoediting in malignant glioma
ES2439580T3 (en) T cell regulation
Jinushi et al. Enhancing the clinical activity of granulocyte‐macrophage colony‐stimulating factor‐secreting tumor cell vaccines
Facciabene et al. Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy
JP5577246B2 (en) Immunity via C-type lectin
EP2862579B1 (en) Tumor immunity
Saha et al. Combination of CTL‐associated Antigen‐4 blockade and depletion of CD25+ regulatory T cells enhance tumour immunity of dendritic cell‐based vaccine in a mouse model of colon cancer
US10753938B2 (en) Beta-catenin inhibitors in cancer immunotherapy
Cheung et al. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer
AU2017276498A1 (en) CALR and JAK2 vaccine compositions
JP2023009120A (en) Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
Tran et al. A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice
Saha et al. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen
Zhou et al. B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer
Zhou Enhanced anti-tumor immunity by breaking immune tolerance
Prasit Harnessing iNKT cells to improve in situ vaccination for cancer therapy
Mesias Unraveling the Signaling Pathways of the CD200 Activation Receptor Family and Their Implications in Regulating Antitumor Response in Glioblastoma
Zheng Two-signal requirement for the development of T lymphocytes
Generoso Six-transmembrane epithelial antigen of the postate (STREAP): a potential target of immunotherapy of prostate cancer.
Bou Nasser Eddine CIITA-induced MHC class II expression in tumor cells: a novel universal strategy of anti-tumor vaccination.
Lundberg On immunotherapy against prostate cancer